More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study
Hidenori Arai,Takafumi Hiro,Takeshi Kimura,Takeshi Morimoto,Katsumi Miyauchi,Yoshihisa Nakagawa,Masakazu Yamagishi,Yukio Ozaki,Kazuo Kimura,Satoshi Saito,Tetsu Yamaguchi,Hiroyuki Daida,Masunori Matsuzaki,JAPAN-ACS Investigators,Takayuki Ito,Hiroaki Takashima,Tadaya Sato,Masato Watarai,Yukio Kazatani,Shinichi Hiramatsu,Hitoshi Hishida,Hiroyuki Naruse,Keijiro Saku,Shin-ichiro Miura,Atsushi Iwata,Sachiro Watanabe,Toshiyuki Noda,Ryuhei Tanaka,Koji Ono,Keigo Dote,Masaya Kato,Shota Sasaki,Kentaro Ueda,Ichiro Inoue,Takuji Kawagoe,Haruo Kamiya,Satoru Suwa,Yuji Nakazato,Kosei Tanimoto,Shinsuke Nanto,Fusako Sera,Masakiyo Nobuyoshi,Hitoshi Yasumoto,Kazuaki Nitsudo,Yasushi Fuku,Hiroshi Nonogi,Yoritaka Otsuka,Nobuaki Kokubu,Hiroshi Iida,Mutsuo Nakayama,Shinichi Minagoe,Hitoshi Nakajima,Masahiro Sonoda,Tetsuro Kouya,Noriyuki Miyamoto,Yoshiyuki Suzuki,Sachie Tagucho,Toru Ujihira,Hironori Saitou,Tetsuya Sato,Akira Itoh,Kei Yunoki,Takashi Honda,Koichi Nakao,Norihiro Yamada,Taiichiro Meguro,Kaname Takizawa,Hiroshi Ogawa,Takahiro Iwami,Sugao Ishiwata,Yo Fujimoto,Yasuhiko Hayashi,Mamoru Toyofuku,Masaya Otsuka,Yasunobu Hirata,Jiro Ando,Takashi Akasaka,Takashi Kubo,Hironori Kitabata,Takashi Fujii,Takayuki Okamura,Jutaro Yamada,Genta Hashimoto,Tatsuhiro Fujimura,Satoshi Ichimiya,Masaaki Kanashiro,Junji Watanabe,Seiji Fukui,Taiki Ohashi,Nobutake Kurebayashi,Kiyoshi Hibi
DOI: https://doi.org/10.5551/jat.5660
2010-10-27
Abstract:Aim: We have shown that aggressive lipid lowering by pitavastatin and atorvastatin results in marked regression of atherosclerotic coronary lesions after acute coronary syndrome (ACS). The purpose of this study was to address the association of lipid levels after statin therapy with regression of atherosclerotic coronary lesions and major cardiovascular events in patients after ACS. Methods: JAPAN-ACS is a prospective, randomized open-label study performed at 33 centers in Japan. Patients with ACS undergoing intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) were randomly assigned to receive either 4 mg/day pitavastatin or 20 mg/day atorvastatin within 72 hours after PCI. IVUS image was obtained in 251 patients, including 73 diabetic patients. Lipid profiles at the end of the study were divided into quartiles and the association with the percent change in non-culprit coronary plaque volume (PV) was assessed in total and diabetic patients. We also studied whether baseline and follow-up levels of HDL-cholesterol are associated with restenosis after PCI. Results: Decreasing LDL-cholesterol, non-HDL-cholesterol, LDL-C/HDL-C ratio, apolipoprotein B quartiles were associated with a progressively smaller plaque burden in total and diabetic patients. In diabetic patients, further reduction of these parameters was associated with a significantly greater reduction in PV. We also found that patients with lower HDL-cholesterol had a significantly higher incidence of target lesion revascularization. Conclusions: Early intensive statin therapy in patients after ACS results in remarkable regression of coronary PV. Diabetic patients can have a benefit with more intensive therapy to achieve a lower target level in Japanese.